[OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER].

(Purpose) We investigated the outcome of selective organ preservation in invasive bladder cancer using chemoradiation therapy. (Patients and method) We examined locally invasive bladder cancer in 60 patients (51 men, 9 women; mean age at treatment 66.1 years) who underwent chemoradiation therapy for bladder preservation in the Department of Urology at Sumitomo Hospital between 2000 and 2015. The clinical stage was T1, T2, T3 and T4 in 4, 24, 17, 4 patients. Our protocol includes transurethral resection of the bladder tumor (TURBT) and 46 Gy radiation (2 Gy/fraction) to the bladder with concurrent cisplatin chemotherapy (20 mg/body/day, 10 days, intravenously). The initial evaluation included urine cytology and transurethral bladder biopsy. If patients developed superficial residual or recurrent cancer, they were treated with TURBT and/or intravesical Bacillus Calmette-Guerin (BCG), while patients with invasive residual or recurrent cancer were advised to undergo a salvage cystectomy. The mean follow-up was 55 months. (Results) The first assessment after the chemoradiation therapy showed that the complete remission rate for evaluable cases was 72% (38/53) and bladder preservation was achieved in 56 patients (93%). The 1-, 3-, and 5-year overall survival rate was 95, 86, and 78%, respectively. The 1-, 3-, and 5-year cancer-specific survival rate was 97, 90, and 85%, respectively. The 5-year patient survival rate with an intact bladder was 68%. Hydronephrosis and cisplatin dose (<200 mg) were independent adverse factors of overall survival in a Cox model (HR 4.5 and 4.1, respectively). (Conclusions) Chemoradiation therapy for invasive bladder cancer can achieve similar survival rate to those in patients treated with radical cystectomy, and enable the majority of patients to preserve the bladder.

Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis.

BACKGROUND: The purposes of this study were to determine whether adjuvant chemotherapy (AC) improved the prognosis of patients with high-risk upper urinary tract urothelial carcinoma (UTUC)and to identify the patients who benefited from AC. METHODS: Among a multi-center database of 1014 patients who underwent RNU for UTUC, 344 patients with ≥ pT3 or the presence of lymphovascular invasion (LVI) were included. Cancer-specific survival (CSS) estimates were calculated by the Kaplan-Meier method, and groups were compared by the log-rank test. Each patient's probability of receiving AC depending on the covariates in each group was estimated by logistic regression models. Propensity score matching was used to adjust the confounding factors for selecting patients for AC, and log-rank tests were applied to these propensity score-matched cohorts. Cox proportional hazards regression modeling was used to identify the variables with significant interaction with AC. Variables included age, pT category, LVI, tumor grade, ECOG performance status and low sodium or hemoglobin score, which we reported to be a prognostic factor of UTUC. RESULTS: Of the 344 patients, 241 (70%) had received RNU only and 103 (30%) had received RNU+AC. The median follow-up period was 32 (range 1-184) months. Overall, AC did not improve CSS (P = 0.12). After propensity score matching, the 5-year CSS was 69.0% in patients with RNU+AC versus 58.9% in patients with RNU alone (P = 0.030). Subgroup analyses of survival were performed to identify the patients who benefitted from AC. Subgroups of patients with low preoperative serum sodium (≤ 140 mEq/ml) or hemoglobin levels below the normal limit benefitted from AC (HR 0.34, 95% CI 0.15-0.61, P = 0.001). In the subgroup of patients with normal sodium and normal hemoglobin levels, 5-year CSS was 77.7% in patients with RNU+AC versus 80.2% in patients with RNU alone (P = 0.84). In contrast, in the subgroup of patients with low sodium or low hemoglobin levels, 5-year CSS was 71.0% in patients with RNU+AC versus 38.5% in patients with RNU alone (P < 0.001). CONCLUSIONS: High-risk UTUC patients, especially subgroups of patients with lower sodium and hemoglobin levels, could benefit from AC after RNU.

[A Case of Bilateral Adrenal Incidentaloma in which MTX-Related Lymphoproliferative Disease Could Be Diagnosed by Computed Tomography-Guided Biopsy and MTX Administration History].

The patient was a 76-year-old man. Because bilateral adrenal tumor (right adrenal gland 7 cm, left adrenal gland 1.5 cm) was detected in by computed tomography (CT) in methotrexate (MTX) administration for articular rheumatism from 2011, he was referred to this hospital in February, 2016. An endocrine examination, and imaging study did not lead to a definitive diagnosis and CT-guided lower needle biopsy was performed. The pathological diagnosis was diffuse large B cell lymphoma. Also, in situ hybridization revealed EBER-positive and the diagnosis of MTX-related lymphoproliferative disease (MTXLPD) was made in conjunction with the medical history. After MTX cancellation, the tumor became markedly smaller. The annual incidence of this disorder in the RA patients during MTX internal use is reported as 0.06%. According to the site of origin, lymphatic extranodal disease accounts for approximately half of the cases, but this is the third case of primary adrenal origin reported.

[A CASE THAT TS-1+CDDP THERAPY WAS EFFECTIVE FOR BLADDER PRIMARY SIGNET RING CELL ADENOCARCINOMA].

Since we experienced a case that S-1+Cisplatin (CDDP) therapy was effective for bladder primary signet ring cell adenocarcinoma of pT4N0M0, we report here the time course of its pathophysiology and the treatment of that patient, and discuss the justification of the chemotherapy for the T4 case with the comparison of the previous cases. The present case is a 66 years old man. Because he was aware of the urinary frequency and the sense of incongruity at abdominal region for approximately three months, he visited our hospital for the consultation of his symptoms in July, 2015. The anterior wall showed a torose lesion by cystoscopy from the left sidewall, and we found the histopathology signet ring cell adenocarcinoma after transurethral resection of the bladder tumor. As a result of thorough investigation of thoracic abdominal CT, whole body PET-CT and endoscopy of the upper gastrointestinal tract, we diagnosed it as bladder primary signet ring cell adenocarcinoma with cT3N0M0. Consequently, we tried total cystectomy in August, 2015, however both bladder and pelvic wall were adhered strongly each other; we gave up the total cystectomy and changed the strategy to the urinary diversion by bilateral ureterocutaneous fistula. A biopsy of the adhesion site of the right pelvic wall showed the invasion of the signet ring cell adenocarcinoma, which enabled us to diagnose as pT4bN0M0. Therefore, we performed the chemotherapy with the S-1+CDDP for 12 courses, 16 months from August, 2015 after the surgery. After the initiation of the chemotherapy, the tumor marker was tended to decrease for eight months, but turned to increase thereafter. Because there was no evidence for neither distant nor lymph node metastases of tumor revealed by CT and the MRI, we diagnosed it as Stable Disease at least by CT and MRI examinations for 16 months. The major side-effects were not found during the strengthened chemotherapy without the recurrence until January, 2017. Since this case is very rare, we report the time courses and treatment strategy of a patient with bladder primary signet ring cell adenocarcinoma.

[A CASE OF PROSTATE CANCER WITH SECONDARY HYPOGONADISM].

A 70 year-old man underwent contrast CT, which revealed his swollen left inguinal and pelvic lymph nodes. The lymph nodes reduced in size without any treatments in a follow-up examination. In 2013, the lymph nodes enlarged again, and FDG-PET/CT showed high value at the prostate and multiple lymph nodes. The levels of serum PSA was high (PSA=682 ng/ml), therefore he underwent a prostate biopsy in his previous hospital and was diagnosed prostate cancer with metastasis of lymph nodes (cT2cN1M1a). Androgen deprivation therapy (ADT) was administered; however, the levels of serum PSA didn't reduce and lymph nodes enlarged further. He was referred to our hospital for further evaluation and treatment. The levels of serum total testosterone before ADT administration at his previous hospital was less than 0.05 ng/ml, which meaned that he had been hypogonadism. Brain MRI revealed a pituitary tumor, and he was diagnosed secondary hypogonadism due to the pituitary tumor. This was thought a rare case of a prostate cancer with secondary hypogonadism which had become castration resistant at the time of diagnosis.

[Renal Epithelioid Angiomyolipoma with Spontaneous Rupture: A Case Report].

A 66-year-old woman was referred to our hospital for a right renal mass found in the examination for sudden right flank pain. Abdominal computed tomography (CT) revealed a right renal tumor, 8.0 cm in diameter, with massive hemorrhage due to spontaneous tumor rupture. After transcatheter arterial embolization, right radical nephrectomy was successfully performed. The histopathological diagnosis of the renal tumor was epithelioid angiomyolipoma (eAML). Postoperative chest CT showed two lung tumors. Therefore, the lung tumors were resected and diagnosed as a primary lung adenocarcinoma and a sclerosing angioma. Although renal eAML is thought to have malignant potential, there has been no local reccurence nor distant metastases of renal eAML 11 months after the surgery.

[CLINICAL SURVEILLANCE OF PROSTATE CANCER--COMPARISON WITH CLINICAL MASS STUDY IN JAPAN].

OBJECTIVES: We report on the treatment trends and outcomes for prostate cancer in our clinic retrospectively, and compared our data with the domestic clinical mass study for prostate cancer. We then validated the legitimacy of our selected therapy for prostate cancer. PATIENTS AND METHODS: Eight hundred and eighteen patients at our clinic had histologically confirmed adenocarcinomas of the prostate between January, 2000 and January, 2013. RESULTS: The age distribution was from 47 to 100 years-old, with a median age of 72 years-old at diagnosis. Clinical TNM staging indicated that 301 cases (36.8%) were stage I, 303 cases (37.0%) were stage II, 101 cases (12.3%) were stage III and 113 cases (13.8%) were stage IV. Three hundred and fifty two cases (43.0%) received some form of androgen deprivation therapy (ADT). Retropubic prostatectomy (RPX) or radiation therapy (RT), including external beam radiation therapy and brachytherapy, was performed in 242 (29.6%) and 136 (16.6%) cases, respectively. The median overall survival was 56.3 months and the respective cause specific 5 year and 10 year survival rates of the 818 cases were 92.0% and 77.8%. Respectively, they were 100% and 100% for T1, 98.7% and 97.4% for T2, 90.7% and 38.5% for T3, and 60.8% and 38.9% for T4. JUA (Japanese Urological Association) Cancer Registration Statistics includes 11,385 eligible cases of prostate cancer, and had the same distribution and the same therapy trends as our data base. NUORG (Nara Uro-oncological Research Group), the data base of 2,303 prostate cancer patients, and our clinical study had the same distribution of D'Amico risk groups. Finally we validated JCAP (Japan Study Group of Prostate Cancer) recommended J-CAPRA scores in our prostate cancer patients who received primary androgen deprivation therapies. Progression free survival and cause specific survival were related to J-CAPRA scores. DISCUSSION/CONCLUSION: The Japanese prostate cancer patients have higher prostate-specific antigen at diagnosis, higher Gleason score and higher clinical stage than the US patients. The higher rate of primary androgen deprivation therapy is characteristic for the Japanese patients.

[Primary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma with Large Cell Transformation of the Prostate : A Case Report].

Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the prostate is rare. MALT lymphoma with large cell transformation like a diffuse large B-cell lymphoma (DLBCL) of the prostate is extremely rare. To the best of our knowledge, only one case has been previously reported. A 65-year-old man with difficulty on urination was referred to our department, in April 2014, because of abnormal findings of magnetic resonance imaging (MRI) and positron emission tomography-computed tomography imaging. Routine laboratory tests including prostate specific antigen and soluble interletkin-2 recepter were within normal limits, and the physical examination was unremarkable. In July 2007 and August 2009, he was submitted for a transrectal prostate biopsy, and then a histological examination for chronic prostatitis. In addition to the biopsy, transurethral resection of the prostate was performed. Histological examination revealed primary MALT lymphoma with large cell transformation of the prostate. Complete clinical investigation, including bone marrow biopsy, did not show any involvement of other sites by lymphoma, he received 3 cycles of chemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by radiation therapy with a total dose of 46 Gy. The patient has been in complete remission for 6 months after the chemoradiation therapy.

[Unilateral synchronous occurrence of renal pelvic urothelial carcinoma and renal cell carcinoma : report of two cases].

Two cases of unilateral synchronous occurrence of renal pelvic urothelial carcinoma and renal cell carcinoma are presented. Case 1 : A 70-year-old woman presented with macroscopic hematuria. Retroperitoneoscopic nephroureterectomy was performed under the diagnosis of renal pelvic carcinoma. Pathological diagnosis was not only renal pelvic urothelial carcinoma but also renal cell carcinoma 1.5×0.5 mm in diameter. Case 2 : A 79-year-old man with hormonal therapy for prostate cancer complained of macroscopic hematuria. Right nephroureterectomy was performed under the diagnosis of right renal pelvic carcinoma and right renal cell carcinoma. Pathological findings were the same as preoperative diagnosis. To our knowledge, 21 cases of unilateral synchronous occurrence of renal pelvic urothelial carcinoma and renal cell carcinoma have been reported in the Japanese literature including our cases and the clinical features are reviewed.

[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].

A 56-year-old man was admitted to our hospital complaining of dyspnea, general fatigue and lumbago. Several examinations revealed severe pancytopenia with disseminated intravascular coagulation (DIC), multiple lymph node metastases, and extremely high serum prostate specific antigen (PSA) level. Hormonal therapy under a diagnosis of advanced prostate cancer was started. Bone marrow biopsy, performed for the assessment of pancytopenia, revealed that there were no hematopoietic cells but only diffuse infiltration of prostate cancer cells. His bone scintigraphy showed a super scan image. Therefore, our diagnosis was prostate cancer with disseminated carcinomatosis of bone marrow. Although the response to hormonal therapy had been initially good, the time to PSA nadir was 9 weeks and he died 34 weeks after the start of the treatment. To our knowledge, 20 cases of prostate cancer with disseminated carcinomatosis of bone marrow have been reported in the Japanese literature including this case and the clinical features are reviewed.

[Giant non-functioning adrenocortical carcinoma effectively treated with preoperative transarterial embolization: a case report].

An 80-year-old women consulted a physician because of weight loss and slight fever. Since a large retroperitoneal tumor was found, the patient was referred to our hospital. Based on abdominal computed tomography, magnetic resonance imaging and blood tests, preoperative diagnosis was non-functioning left adrenal tumor, 13 cm in diameter. Preoperative abdominal angiography revealed that the tumor was supplied blood by the left adrenal artery, left renal artery through left renal upper segment, splenic artery, pancreas tail artery, and middle colic artery. We performed transcatheter arterial embolization (TAE) of some of these tumor-supplying vessels. Three days after the TAE, adrenalectomy was performed without blood transfusion. Histopathological examination of the tumor was adrenocortical carcinoma of low grade malignancy.

[Testicular cancer with inguinal lymph node metastasis in a patient with prior orchiopexy for undescended testis: a case report].

A 36-year-old man referred to our hospital with the chief complaint of painful left inguinal mass and fever. He had undergone left orchiopexy for undescended testis at 10 years of age. With the suspicion of an incarceration of inguinal hernia, an operation was performed. However, there was no hernia sac, and only swelling inguinal lymph nodes were found. Pathological diagnosis of the nodes was metastatic embryonal carcinoma, with suspicion of testicular origin. As scrotal ultrasonography revealed a hypoehcoic mass within the left atrophic testis, left high orchiectomy was performed. Pathological diagnosis of the left testicular mass was seminoma. A definite diagnosis was left testicular cancer, mixed type of seminoma and embryonal carcinoma, with inguinal nodes metastasis, pT1N2M0. He received 3 courses of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, and there has been no sign of metastasis nor recurrence 18 months after the operation. To our knowledge, this is the 11th case in Japan of testicular cancer with inguinal node metastasis in a patient with prior orchiopexy for undescended testis.

[Metachronous bilateral testicular tumors in a case of male infertility].

A 42-year-old man referred to our hospital with the chief complaint of a solid mass of right scrotal contents. As ultrasonography revealed a right testicular tumor, right high orchiectomy was performed and the pathlogical diagnosis was testicular seminoma. At the age of 35-year-old, he was admitted to another hospital for male infertility due to azoospermia. Because left testicular tumor was found, left high orchiectomy was performed, with right testicular biopsy and testicular sperm extraction of the right testis at the same time. Pathological diagnosis revealed left testicular seminoma and no malignancy of the right testicular biopsy specimen. After the second operation, he has been receiving androgen replacement therapy, with no evidence of tumor recurrence.

[Giant solitary fibrous tumor of a kidney: a case report].

Renal solitary fibrous tumor (SFT) has been reported infrequently. We report a case in a 39-year-old woman with a 9-month history of sense of abdominal fullness. Computed tomography revealed well-encapsulated heterogeneous tumors involving the lower pole of the left kidney with left renal vein extension. The tumors measured approximately 20 cm in diameter and displaced adjacent organs. We performed preoperative transcatheter arterial embolization of the left renal artery. Left nephrectomy with complete tumor resection was achieved without major complications. The tumors were well-circumscribed and composed of spindle cells in a collagenous stroma. Immunohistochemistry showed reactivity for CD34 and bcl-2. Immunohistochemical stains for c-kit and CD10 were negative. A diagnosis of SFT was made based on light microscopy and immunohistochemistry. The patient is alive with no evidence of disease 6 months after the operation. This case is the largest renal SFT in the Japanese literature.

[A case report of retroperitoneal fibrosis associated with IgG4-related sclerosing disease].

A 67-year-old man had undergone a right ureteronephrectomy because of a right ureter tumor, but the pathological diagnosis was inflammatory tissue with plasma cells, lymphocytes, and fibrosis. About 3 years later, abdominal computed tomography (CT) revealed a solid tumor at the left renal hilus. We resected the tumor and the pathological diagnosis was the same as before. More than 2 years later, because of elevated pancreatic enzymes, immunoglobulin G (IgG) and IgG4, more detailed examinations ware done, and he was diagnosed with IgG4-related autoimmune pancreatitis. We believe that the retroperitoneal tumor was retroperitoneal fibrosis associated with IgG4-related sclerosing disease. Now, he is being treated with steroid therapy. IgG4-related sclerosing disease is a systemic disease whose concept is now being established. Much more work is needed to understand this disease.

[Case report of prostatic stromal tumor of uncertain malignant potential (STUMP)].

A 64-year-old male was referred to our hospital with a prostate tumor accompanying a huge prostatic cyst. He had been followed up for 10 years by another urologist, and received several prostate biopsies, which failed to make a definite diagnosis. We carefully reviewed the biopsy slides and diagnosed the lesion as prostatic stromal tumor of uncertain malignant potential (STUMP). We performed radical prostatectomy. From the excised specimen, we confirmed the diagnosis of prostatic STUMP. Eight months later, there was no sign of metastasis or recurrence.